MaveriX Oncology Competitors and Similar CompaniesClear all
MaveriX Oncology's competitors and similar companies include Avectas, Immunicom, Nuvectis Pharma and ViewRay.
 MaveriX Oncology MaveriX Oncology is a biotechnology company focused on the discovery, development, and commercialization of targeted small-molecule cancer chemo-immunotherapies. |  Avectas Avectas is a company developing a non-viral cell engineering technology which efficiently engineers therapeutic cells, at scale, while maintaining optimal cell functionality. |  Immunicom Immunicom is a company that develops and commercializes a non-drug-based cancer therapy in order to reduce treatment side effects and enhance its response rates. |  Nuvectis Pharma Nuvectis Pharma (formerly known as Centry Pharma) is a biopharmaceutical company focused on precision medicines for cancer treatment. |  ViewRay ViewRay is a company that designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system. | |
Founding Date | Founding Date 2014 | Founding Date 2010 | Founding Date 2013 | Founding Date 2020 | Founding Date 2004 |
Type | Type Private | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Palo Alto, US HQ | Locations Kildare, IE HQ Cambridge, US | Locations San Diego, US HQ | Locations Fort Lee, US HQ | Locations Oakwood Village, US HQ Mountain View, US |
Employees | Employees 3 | Employees 40 | Employees 22 | Employees 6 | Employees 29510% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 146.8 m | Valuation ($) N/A |
Financial | |||||
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $2.1m (FY, 2025) | Cost of goods $92.2m (FY, 2022) |
Net income | Net income N/A | Net income N/A | Net income N/A | Net income ($26.4m) (FY, 2025) | Net income ($107.3m) (FY, 2022) |
Funding | |||||
Latest funding round | Latest funding round $ 6.5m (over 6 years ago) | Latest funding round $ 20m (about 6 years ago) | Latest funding round $ 1.9m (over 6 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 6.5m | Total funding raised $ 32.6m | Total funding raised $ 21.9m | Total funding raised $ 15.3m | Total funding raised $ 84.8m |
For sources of this data, please see the company profile
View Company Profiles
Avectas
HQ
Kildare, IE
Employees
40
Avectas is a company developing a non-viral cell engineering technology which efficiently engineers therapeutic cells, at scale, while maintaining optimal cell functionality.
View companyImmunicom
HQ
San Diego, US
Employees
22
Immunicom is a company that develops and commercializes a non-drug-based cancer therapy in order to reduce treatment side effects and enhance its response rates.
View companyNuvectis Pharma
HQ
Fort Lee, US
Employees
6
Nuvectis Pharma (formerly known as Centry Pharma) is a biopharmaceutical company focused on precision medicines for cancer treatment.
View companyViewRay
HQ
Oakwood Village, US
Employees
295↑ 10% increase
ViewRay is a company that designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system.
View company